HbA1c <7.5% (Mild hyperglycemia): it is Highly reversible
First-line therapy: Lifestyle modifications (diet and exercise) + Metformin. Metformin is the preferred initial drug of choice due to its efficacy, safety, and minimal risk of hypoglycemia ( Drop in Blood Glucose Level below Normal on Consuming) Follow-up: Assess response in 3 months. If HbA1c is still above target, consider dual therapy.
HbA1c 7.5%-8.9% (Moderate hyperglycemia):
Dual therapy: Metformin + second agent based on patient profile:
Sulfonylurea (e.g., glimepiride): If cost is a concern and no risk of hypoglycemia.
SGLT-2 inhibitors (e.g., empagliflozin): For cardiovascular or renal benefits.
DPP-4 inhibitors (e.g., sitagliptin): For weight neutrality and low hypoglycemia risk.
GLP-1 receptor agonists (Semaglutide): For added weight loss benefits.
GLP-1 RA , slows food passage through your Stomach , makes your brain think you are full & you tend to consume less food = weight loss + control of Sugar as well (layman Expl.)
Follow-up: Reassess HbA1c after 3 months. Adjust therapy if needed.
HbA1c ≥9% (Severe hyperglycemia):
Symptomatic or ketosis: Initiate insulin with or without OHAs.
Non-symptomatic:
Triple therapy with Metformin + two additional agents:
SGLT-2 inhibitor + DPP-4 inhibitor or
SGLT-2 inhibitor + sulfonylurea.
For weight loss, GLP-1 receptor agonists can replace one OHA.
Monitoring and Adjustments:
Monitor HbA1c every 3-6 months.
Adjust therapy based on HbA1c targets, side effects, and patient preferences.
Special Considerations:
Elderly or frail: Use agents with low hypoglycemia risk (DPP-4 inhibitors or SGLT-2 inhibitors).
Obesity: Prefer GLP-1 receptor agonists or SGLT-2 inhibitors for weight management.
Cardiovasculardisease: PrioritizeSGLT2 inhibitors or GLP1 receptor agonists
